ChemSpider 2D Image | Udenafil | C25H36N6O4S

Udenafil

  • Molecular FormulaC25H36N6O4S
  • Average mass Da
  • Monoisotopic mass Da
  • ChemSpider ID5293720

More details:



Featured data source



Validated by Experts, Validated by Users, Non-Validated, Removed by Users

268203-93-6 [RN]
3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzenesulfonamide [ACD/IUPAC Name]
3-(1-Méthyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-méthyl-2-pyrrolidinyl)éthyl]-4-propoxybenzènesulfonamide [French] [ACD/IUPAC Name]
3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxybenzolsulfonamid [German] [ACD/IUPAC Name]
8551
Benzenesulfonamide, 3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxy- [ACD/Index Name]
L5IB4XLY36
UDENAFIL, (R)-
UDENAFIL, (S)-
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

DA-8159 [DBID]
70O28QX6RP [DBID]
VAG839S052 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous
    • Safety:

      G04BE11 Wikidata Q4815980
    • Bio Activity:

      Metabolic Enzyme/Protease; MedChem Express HY-18253
      Others MedChem Express HY-18253
      PDE MedChem Express HY-18253
      Udenafil(DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction. MedChem Express
      Udenafil(DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction.; Target: PDE5; Udenafil is an oral PDE5 inhibitor. MedChem Express HY-18253
      Udenafil(DA8159) is a PDE5 inhibitor used in urology to treat erectile dysfunction.;Target: PDE5Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ratio of udenafil was higher than tadalafil. These findings may help in the assessment of the feasibility of using PDE5 Is to concurrently treat both LUTS and erectile dysfunction [1]. After 12 weeks of treatment, the patients treated with udenafil showed significantly greater change from baseline in the IIEF-EF domain score compared with placebo (placebo, 0.20; 100-mg udenafil, 7.52; and 200-mg udenafil, 9.93, respectively) (P < 0.0001). udenafil significantly enhanced the rates of successful penetration (SEP Q2) and maintenance of erection (SEP Q3) (P < 0.0001) [2]. MedChem Express HY-18253

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module

No predicted properties have been calculated for this compound.

Click to predict properties on the Chemicalize site






Advertisement